European Journal of Biomedical and Pharmaceutical Sciences

A COMPARATIVE STUDY ON SAFETY, EFFICACY & COST EFFECTIVENESS OF FERRIC CARBOXYMALTOSE & IRON SUCROSE IN DIALYSIS PATIENTS AT A TERTIARY CARE HOSPITAL

Ansu Anna Dan*, Merlin K. Jacob, Sneha Prabha, Apollo James and T. Sivakumar

ABSTRACT

The objective of our study was to evaluate the safety, efficacy and cost effectiveness of FCM, compared to IV iron sucrose in dialysis patients who have iron deficiency anemia. A prospective observational comparative study was carried out in 69 hemodialysis patients during the period of 6 months in a tertiary care hospital in Southern India. Our results showed that Ferric Carboxymaltose (FCM) was more efficacious, safer and cost effective compared to iron sucrose. Our study highlights on primary efficacy parameters- Hemoglobin(Hb), ferritin, serum iron and transferrin saturation (TSAT). In case of Hb, TSAT, serum iron FCM showed a mean increase 5.267g/dL, 3.2%, 20. 02 μg/dL while iron sucrose showed only 3.30 g/dL, 1.781%, 16.4% μg/dL respectively. While comparing the mean value of serum ferritin levels, FCM showed a decreased level of 69.25% ng/mL decrease whereas for iron sucrose only 53.81 ng/mL was observed. At least one drug-related treatment-emergent ADR occurred in 7 of 40 (17.3%) subjects in the FCM group and 13 of 29 (44.8%) subjects in the iron sucrose group. FCM should be cost effective for the patient and maximal time efficiency for the doctors and healthcare professionals than the iron sucrose. FCM has the advantage of allowing more iron to be administered in fewer infusions in patients with chronic kidney disease. FCM was superior to iron sucrose in replenishing the iron stores.

Keywords: Ferric Carboxymaltose, Hemodialysis, Iron sucrose.